drugset / Trial / NCT05305105
Effects of Psilocybin in Post-Treatment Lyme Disease
Phase 1
Completed
20 enrolled
Johns Hopkins University
Steven & Alexandra Cohen Foundation · collabUsona Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).
Timeline
- Start
- 2022-07-01
- Primary completion
- 2024-10-26
- Completion
- 2025-04-07
Publications
- Background Fallon BA, Zubcevik N, Bennett C, Doshi S, Rebman AW, Kishon R, Moeller JR, Octavien NR, Aucott JN. The General Symptom Questionnaire-30 (GSQ-30): A Brief Measure of Multi-System Symptom Burden in Lyme Disease. Front Med (Lausanne). 2019 Dec 6;6:283. doi: 10.3389/fmed.2019.00283. eCollection 2019.
- Background Rebman AW, Bechtold KT, Yang T, Mihm EA, Soloski MJ, Novak CB, Aucott JN. The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome. Front Med (Lausanne). 2017 Dec 14;4:224. doi: 10.3389/fmed.2017.00224. eCollection 2017.
- Garcia-Romeu A, Naude GP, Rebman AW, So S, Yaffe A, Geithner I, Kozero EA, Yang T, Soloski MJ, Aucott JN. Pilot study of psilocybin in patients with post-treatment lyme disease. Sci Rep. 2026 Feb 25;16(1):7497. doi: 10.1038/s41598-026-38091-9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 15 mg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |